+ monocytes. Functions of the classical and nonclassical monocytes have been clearly defined. Classical monocytes play an important role in the initiation and progression of the inflammatory response, having proinflammatory roles in multiple chronic diseases, including atherosclerosis, 1 cancer, 2 and rheumatoid arthritis. 3 Nonclassical monocytes, in contrast, seem to play a role in the resolution of inflammation and have the ability to clear dying cells, 4 viruses, 5 and tumor cells from the circulation. 6 The function of the intermediate subset is mixed, with studies supporting both proinflammatory 7, 8 and anti-inflammatory 9, 10 roles.
See cover image
Monocytes have been shown to play crucial roles in coronary artery disease (CAD). Frequencies of all 3 circulating human monocyte subsets have been linked to various stages of CAD. 11, 12 Most of our current knowledge on monocyte function in CAD has arisen from mouse studies. Mouse monocyte subsets are classified on their differential expression of Ly6C, Treml4 (triggering receptor expressed on myeloid cells like-4), and CD43: Ly6C + nonclassical monocytes. Monocyte recruitment to the aortic wall seems to be proportional to disease severity. 13 Cell-tracking studies have demonstrated that both classical and nonclassical subsets can enter atherosclerotic lesions.
14, 15 Tacke et al 14 showed that nonclassical Ly6C lo monocyte recruitment is reduced by CCR5 blockade and classical Ly6C hi recruitment by either CCR5, CCR2, or CX3CR1 blockade. And when all 3 of these chemokine receptors are blocked, a remarkable reduction in atherosclerotic lesion size is achieved. 11 After entering the atherosclerotic lesion, classical monocytes can differentiate into lipid-laden foam cell macrophages which in turn contribute to lesion destabilization. 16 In contrast, nonclassical monocytes display a patrolling behavior characterized by crawling along vascular endothelium and are thought to play an atheroprotective role maintaining endothelial homeostasis. 4, 17, 18 We have shown that this patrolling behavior is increased in early atherosclerotic vessels. 18 Nonclassical monocytes also preferentially scavenge and accumulate lipids including oxLDL (oxidized low-density lipoprotein) from the vasculature, and increase in numbers in response to sensing oxLDL. [18] [19] [20] Mice deficient for Nr4a1, a transcription factor necessary for Ly6C lo monocyte development, lack nonclassical monocytes. 21, 22 In support of the notion that nonclassical monocytes are atheroprotective, Nr4a1 −/− mice either crossed with the atherogenic ApoE −/− mice or after bone marrow transplantation to atherogenic Ldlr −/− mice fed a Western diet showed a 3-fold increase in atherosclerotic lesion area. [23] [24] [25] Thus, nonclassical monocytes may be important in reducing CAD risk. Nonclassical monocytes in this regard are an attractive cell type for CAD biomarker discovery to assist in early CAD diagnosis as well as an important target to reduce CAD risk.
Recent studies have used the high dimensionality of mass cytometry to discover heterogeneity in cell phenotypes. 26, 27 Conventional flow cytometry is limited by the number of independent markers that can be analyzed simultaneously and can be problematic because of the spectral overlap of fluorophores. Cytometry by time-of-flight (CyTOF; mass cytometry) uses heavy metal-conjugated antibodies in tandem with time of flight mass spectrometry to measure protein abundances at a single-cell resolution, 28 thereby providing the technical means to overcome these challenges and to allow for deeper analysis of cell heterogeneity. Importantly, mass cytometry data can be analyzed in an automated high-dimensional manner, which allows unbiased objective separation of cells and subsets solely based on their expression patterns. In the current study, we used the high dimensionality of mass cytometry to explore the heterogeneity of nonclassical monocyte subsets in blood of healthy humans and apply this gained knowledge to humans with CAD.
Materials and Methods
A detailed data analysis section is available in the online-only Data Supplement. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Human Subjects
Heparinized blood from 12 healthy volunteers was obtained after written informed consent under the guidelines of the Institutional Review Board of the La Jolla Institute for Allergy and Immunology and in accordance with Department of Health and Human Services Policy for Protection of Human Research Subjects (IRB VD-057-0217).
Donor characteristics are described in Table I in the online-only Data Supplement. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque PLUS (GE Healthcare Biosciences AB) and SepMate-50 (Stemcell Technologies Inc) according to the manufacturer's protocol.
Samples From Human Subjects With CAD
Frozen PBMCs from 18 human subjects were obtained from the Coronary Assessment in Virginia cohort. 29 It includes patients from 30 to 80 years of age undergoing a medically necessary cardiac catheterization. Exclusion criteria: current acute coronary syndrome, cancer, autoimmune disease, anemia, pregnancy, HIV, immunosuppressive therapy, prior organ transplantation. Donor characteristics are described in Table II in the online-only Data Supplement. Quantitative coronary angiography was performed and the percent stenosis was calculated by 2 independent blinded investigators using Artis Workplace software (Siemens Medical Solutions). The Gensini Severity Scoring system was used to estimate CAD burden. 30 Protocols and procedures were approved by the Institutional Review Board at the University of Virginia (IRB HSR no. 15328) and blood was obtained after written informed consent.
Mass Cytometry
Directly conjugated antibodies were purchased from Fluidigm and purified antibodies were ordered from the companies listed in Table  III in the online-only Data Supplement. Conjugations were performed with the Maxpar X8 Multi-Metal Labeling Kit (Fluidigm) according to the manufacturer's instructions.
Cells were resuspended at 1×10 7 cells/mL and stained with 5 mmol/L Cisplatin (Fluidigm; live/dead), antibody cocktail (Table  III in the online-only Data Supplement) , and 125 nM Ir-Intercalator (Fluidigm) according to Fluidigm protocols. Cells were counted on a BD Accuri C6. Before acquisition on CyTOF Helios (Fluidigm), cells were resuspended at 2×10 6 cells/mL in 0.1×EQ Four Element Calibration Beads (Fluidigm). Batch effects and signal drifting were minimized by tuning every 6 hours during long runs ( Figure I in the online-only Data Supplement). Data was normalized using the Matlab-based Normalizer R2013a_Win64.
To test for reproducibility between CyTOF runs, the same donor was included in each run. About 100 mL of heparinized blood was drawn from a healthy control donor, PBMCs were isolated and aliquots were frozen (90% fetal bovine serum+10% dimethyl sulfoxide in a Mr Frosti) and stored in the liquid nitrogen until use. With every CyTOF run 1 vial was taken along for staining and acquisition. A CD45 + t-distributed stochastic neighbor embedding (t-SNE), 31,32 a nonlinear dimensionality reduction method placing high-dimensional data into 2-dimensional space using pairwise comparison of cellular phenotypes, was generated separately for each of these samples and shows a highly similar population map with comparable population frequencies, indicating minimal batch effects ( Figure I in the onlineonly Data Supplement). Histograms for each marker on total monocytes from both these 2 control samples ( Figure IIA 
Mass Cytometry Data Analysis
All gating and t-SNE was performed in Cytobank (Cytobank Inc). . 33 Protein expression was normalized using an arcsinh transformation (cofactor=5). 34 As recommended by the CyTOF workflow, 34 all monocytes from 12 healthy individuals were pooled (=227 371 total). Clustering was performed based on a self-organizing map (SOM) method using FlowSOM (v1. 4 
Monocyte Subset Gating
Diffusion map 38 was used to develop an accurate gating strategy. For conventional flow cytometric validation, 0.5 mL heparinized blood from 4 healthy volunteers was stained with Live/Dead Fixable Yellow (Invitrogen) and the classical or CD16 + monocyte antibody panels (Major Resources Table) . Samples were acquired on a BD LSRII (Becton Dickinson) cytometer. Discrimination index was calculated.
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RNA Sequencing
CD16
+ monocyte subsets (3 nonclassical, 1 intermediate) from 3 healthy donors were sorted into Trizol-LS on a BD FACSAria-II. RNA was isolated using the Direct-zol RNA MiniPrep kit (Zymo Research) according to the manufacturer's instructions.
RNA quality was measured using the Agilent Bioanalyzer2100. Twelve human stranded cDNA libraries were prepared using the SMARTer Stranded Total RNA-Seq Pico Input Mammalian kit. Libraries were sequenced on an Illumina HiSeq2500 using 50 bp single-end reads, generating 15 to 26 million reads per library.
Raw reads were inspected by FastQC 40 to screen for adapter sequence contamination and to assess per-base and per-read quality scores. Reads were mapped to human hg38 using subreadalign (v1.5.3). 41 Reads overlapping with the National Center of Biotechnology Information RefSeq annotation (featureCounts v1.5.3) 42 were used for downstream analysis. Differential expression testing was performed using linear model analysis (function voom from limma v3.33.7) 43 with scaling normalization factors estimated using edgeR. Differentially expressed genes were called with log fold-change cutoff=1.5 and P value cutoff=0.05. Table in the online-only Data Supplement) on a Western diet for 1 week were prepared for imaging as described in Marcovecchio et al. 18 All imaging was performed on a Leica TCS SP8 confocal microscope with a 25x/0.95 HCX IRAPO water objective using Leica Software. Five minutes before imaging, mice were injected with CD9-AF647 and CD31-BV421 (Major Resources Table in the online-only Data Supplement). All experiments followed the guidelines of the La Jolla Institute for Allergy and Immunology Animal Care and Use Committee, and approval was obtained from La Jolla Institute for Allergy and Immunology according to criteria outlined in the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health.
Mouse Monocyte Intravital Imaging
oxLDL Uptake
Either 20 μL of 0.5 mg/mL DiI-labeled LDL or oxLDL was added to 400 μL of heparinized donor blood (n=6) and incubated for 20 minutes at 37°C. Cells were stained with Live/Dead Fixable Yellow (Invitrogen) and the classical monocyte antibody panel (Major Resources Table in the online-only Data Supplement). Samples were acquired on a BD LSRII (cytometer).
CXCL16 Migration
Transwell migration was performed through a 5.0 μm pore polycarbonate membrane (Corning). CD16 + monocytes were sorted from healthy donor PBMCs (n=4). Monocytes were added to each upper compartment (5x10 5 cells) and were allowed to migrate to 100 ng/ mL CXCL16 (R&D) in the lower chamber. After 3 hours, cells from upper and lower compartments were collected for flow cytometry (Major Resources Table in the online-only Data Supplement) and analyzed using FlowJo (v10.0.8).
Endothelial Cell Adhesion
Human aortic endothelial cells were grown until confluent on 48-well plates in EBM2 medium (Lonza) and either stimulated with or without 0.5 μg/mL LPS for 4 hours. About 100 000 sorted Slan + (6-sulfo-LacNac) or Slan − CD16 + monocytes were left to adhere for 60 minutes. Wells were washed twice with warm medium, fixed with 2% paraformaldehyde and attached cells were counted manually by phase-contrast microscopy in 5 random areas per well.
Efferocytosis
Mouse thymus was seeded onto 100×20 mm petri dishes (Corning) in DMEM 10% fetal bovine serum. Dexamethasone was added at a
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Mass cytometry
Computational analyses concentration of 2 mmol/L for 4 hours, and apoptotic thymocytes were stained with CellTracker Orange (Life technologies) according to manufacturer's protocol. Degree of apoptosis was verified with Annexin-PI (Life technologies). Apoptotic thymocytes (4x10 6 ) were added to 400 uL of human blood (n=6) and incubated at 37°C for 60 minutes. Samples were stained for CD16 + monocyte clusters, acquired on a BD LSRII and analyzed using FlowJo (v10.0.8).
Statistical Analysis
Data in Figure 5A and 5B are reported as mean±SEM and analyzed with a 2-tailed Mann-Whitney U test after one of the groups failed the Shapiro-Wilk normality test. Pearson correlation was performed for Figure 5C . Data in Figures 3 and 6 are reported as mean±SD and analyzed with the 2-tailed unpaired student t test after passing the Shapiro-Wilk normality test. T tests did not need to be Welch corrected because variances were not found unequal as determined by an F-test. A P<0.05 was considered statistically significant.
Results
Mass Cytometry for Studying Human Monocytes
Human monocyte subsets have typically been defined using only CD14 and CD16 as surface markers. In this study, we first examined monocyte heterogeneity in peripheral blood of healthy human subjects using mass cytometry and subsequent computational data analysis ( Figure 1A ). Fresh blood samples obtained from 12 healthy human donors (Table I in the online-only Data Supplement) were analyzed by CyTOF using a panel of 39 antibodies mainly focused on monocyte phenotypes. Our panel consisted of antibodies against cellsurface proteins known to be expressed on monocytes that were specific for cell adhesion/migration, survival, antigen presentation, and cell activation ( Figure 1B ; Table III in the online-only Data Supplement).
We used t-SNE to gate on live (Cisplatin A, FlowSOM with consensus clustering was used on the total monocyte population of 12 healthy donors combined and resulted in 8 monocytes subsets. A nonlinear dimensionality reduction method, t-SNE, was used to visualize the 8 monocyte subsets into 2-dimensional (2D) space. B, Monocyte subsets were presented as a minimal spanning tree (MST) of 100 nodes from a self-organizing map (SOM) method using FlowSOM in which each node includes phenotypically similar cells and the size of the node indicates the number of cell events. The tree nodes were colored using 3 colors, white, gray, and black (representing the known 3 subsets defined by manual gating and their frequencies in each node) and background colors illustrating the corresponding FlowSOM subset from A in this figure. C, Subset frequencies were determined for each donor. D, Heatmap of the median expression of 36 markers across the 8 monocyte subsets. The color in the heatmap represents the median of the arcsinh for each subset (centroids) with 0-1 transformed marker expression. The dendrogram represents the hierarchical similarity for subsets (columns) and markers (rows) using hierarchical clustering with Euclidean distance and linkage:average agglomeration. E, Monocyte subsets were mapped onto a 2-dimensional diffusion map to estimate the phenotypic similarities. The closer the populations of cells are on a diffusion map the more phenotypically similar they are. The diffusion map was made using the arcsinh transformed median intensities resulting from FlowSOM clustering. C indicates classical; I, intermediates; N, nonclassicals; and t-SNE, t-distributed stochastic neighbor embedding.
blood monocytes, respectively. Phenotypic heterogeneity within monocytes was evident by proteins including CD86, CD36, Slan, and CD9 which showed differential expression within each defined monocyte population ( Figure IIIC in the online-only Data Supplement).
Human Monocytes Are Heterogeneous in Phenotype
To further explore the heterogeneity of monocytes, we first used FlowSOM, a SOM-based method, followed by a consensus clustering algorithm to cluster and identify monocyte subsets. Using FlowSOM, we focused our analysis exclusively on monocytes (pink gate Figure IIIB in the online-only Data Supplement) and identified 8 monocyte subsets present in the blood of healthy human subjects as shown superimposed on the t-SNE map in Figure 2A . We superimposed CD14 and CD16 on this t-SNE map to illustrate where the classical and nonclassical monocytes are located ( Figure IVD in the online-only Data Supplement). We found that 3 distinct FlowSOM-identified subsets fall within the nonclassical monocyte population (subsets 4+5+7) and 4 subsets belong to the classical monocytes (subsets 1+2+6+8); while the intermediate monocyte population surprisingly consisted of a single subset (subset 3). We validated our clustering using an independent method, PhenoGraph. PhenoGraph resulted in highly similar clustering as FlowSOM with a correlation score of 0.92 ( Figure IVE We found that every FlowSOM subset is present in every donor, but with a certain degree of interindividual variation ( Figure 2C ). In Figure 2C , the color of each subset represents the subsets shown in similar colors in Figure 2A and 2B. To define the phenotypes of each subset, we generated a heatmap showing the median intensity of each phenotypic marker we measured ( Figure 2D ). In agreement with previous findings, FlowSOM identified a classical CD14 + IgE + monocyte subset (subset 8). 44 In comparison to all other monocyte subsets, classical monocyte subset 6 seems to have the lowest expression of common monocyte markers HLA-DR, CD86, CD11a, and CD11c. Classical subset 1 has high CD9 and CD61 expression and is the only monocyte subset showing TREM-1 positivity. As expected, Intermediate subset 3 and nonclassical subsets 4, 5, and 7 all have a high CX3CR1 and CD16 expression. Strikingly, nonclassical subset 4 seems to be high for CD61 and CD9, pointing to a possible role in cell adhesion and platelet binding. Next, we generated a diffusion map to estimate the phenotypic similarities of the different subsets. The closer the populations of cells are on a diffusion map the more phenotypically similar. The classical monocyte subsets appeared closer in proximity to each other than did the nonclassical monocyte subsets ( Figure 2E ), suggesting more phenotypic heterogeneity among the nonclassical monocyte populations.
The cell-surface markers that best discriminated between the FlowSOM-defined classical subsets were identified using a diffusion map ( Figure 3A) . IgE clearly identifies subset 8 and CD61 or CD9 marks subset 1. Subset 2 and 6 could be distinguished from one another by CD93 and CD11a expressions.
We developed a conventional gating strategy ( Figure VA in the online-only Data Supplement), allowing us to investigate several functions of the classical subsets ( Figure 3B through  3D) . With ki67 staining, we found classical monocytes to be more proliferative than the nonclassicals as previously shown by Steffen Jung. 45 However, no differences in ki67 were found between our 4 classical subsets ( Figure 3B ). Classical monocytes are known to have a high CD36 expression, 18 which is one of the most important scavenger receptors when it comes to oxLDL uptake. When we investigated both LDL ( Figure 3C ) and oxLDL ( Figure 3D ) uptake more closely, we found that the 4 classical subsets did not differ from one another about these processes. Based on these findings and our significant research interest in nonclassical monocytes, we focused the remainder of our study on nonclassical monocyte heterogeneity.
Nonclassical Monocyte Heterogeneity
Of the 3 nonclassical monocyte clusters, we observed 2 distinct Slan + populations in the nonclassical monocyte group, each with varying expression of Slan ( Figure 2D ). Slan is an unsialylated O-linked carbohydrate modification of P-selectin glycoprotein 1 (PSGL-1 or CD162). 46 Subsets 4 and 5 showed high expression of Slan (termed Slan + ) and subset 7 had no expression of Slan (termed Slan − ; Figure 2D ). Slan has mostly been used as a phenotypic marker to separate intermediate monocytes (which are also Slan − ) from nonclassical monocytes (Slan + ). 47 The cell-surface markers that best discriminated between the FlowSOM-defined monocyte subsets were identified using a diffusion map ( Figure 4A ). Subsets 4 and 5 are best described by Slan positivity and can be distinguished from one another by CD61 and CD9, while both subsets 3 and 7 have no Slan expression. Subset 3 (intermediate monocytes) has higher HLA-DR, CD14, CCR2, and CD36 expression compared with subset 7 ( Figure 4A ). Based on this information, we designed a conventional flow cytometry gating strategy ( Figure VB in the online-only Data Supplement), so that each of the nonclassical monocyte subsets could be functionally studied. Human peripheral blood was stained for conventional flow with a viability dye and a panel of 7 cell-surface markers: CCR2, CD14, CD16, CD9, Slan, CD36, HLA-DR and a lineage cocktail (CD1c+CD3+CD19+CD66b +CD161). To illustrate the ability of these cell-surface markers to distinguish among monocyte clusters, the average discrimination index was calculated (Table IV in + subsets (intermediates and nonclassicals), demonstrating that these subsets can be sorted for clinical studies.
Intraindividual Variability and Aging
Intraindividual variability can affect clinical study outcomes, so we examined intraindividual day-to-day variation in the 8 monocyte subset frequencies ( Figure VIA in the online-only Data Supplement). We analyzed blood draws from multiple healthy donors on 3 consecutive days (all drawn in the morning) using conventional flow cytometry. Some intraindividual day-to-day variation was found in the intermediate (subset 3) and nonclassical (subset 4) frequencies. Classical subset 1 had a great amount of variation (mostly attributed to 1 donor), while the coefficient of variation was below 20% for most subsets. The overall smallest intraindividual day-to-day variation was found in classical subsets 2 and 6. All coefficient of variation percentages were similar to those of previously published data for total monocytes (coefficient of variation range ≈18% to 20%).
In addition, we investigated the effect of aging on monocyte subset frequencies in healthy donors. Donor age ranged from 23 to 72 years old. For each decade, 2 male and 2 female donors were included. A Spearman correlation analysis on age versus monocyte subset frequencies showed no correlations of any monocyte subset with aging ( Figure VIB in the onlineonly Data Supplement).
RNA-Sequencing Analysis of Nonclassical Monocyte Subsets
To shed some light on their possible functions, we first used our developed sorting strategy (Figure VB in the online-only Data Supplement) to perform RNA sequencing on all 4 CD16 + subsets (3-5 and 7; Figure 4) . Overall, the 3 nonclassical subsets were similar. However, 48 unique genes including 3 unannotated genes could distinguish the subsets despite their low gene expression ( Figure 4B ). We generated a heatmap of the 45 differentially expressed genes among all 3 nonclassical subsets ( Figure 4C) + monocytes (intermediate subset 3 and nonclassical subset 7). As a β-1,3-galactosyltransferase family member, this enzyme may in part be responsible for generating the Slan structure on PSGL-1. 49, 50 In addition, SLC35G2 a member of the human nucleotide sugar transporter family solute carrier 35 (SLC35) was upregulated in Slan + monocytes and may be involved in the transport of one of the sugar groups needed to generate the Slan residue. 51 Another interesting characteristic of the Slan + nonclassical monocytes is their higher CXCR6 mRNA expression compared with Slan − monocytes (intermediate subset 3 and nonclassical subset 7). When comparing clusters 4 and 5 within the Slan + nonclassical population, a total of 16 differentially expressed genes were found. Cluster 4 had higher ITGA2B (CD41) and ITGB3 (CD61) mRNA expression as was expected based on the CyTOF data in Figure 2 . Some of the upregulated genes in subset 4, such as MMRN1, SELP, ITGA2B, and TUBB1 are known to be expressed primarily in platelets and megakaryocytes. 52 Since a highly similar nonclassical CD9 + monocyte cluster 4 was present in mice ( Figure Figure VIIB in the online-only Data Supplement, multiple monocytes were observed to be patrolling (indicated by white boxes), of which several were found positive for CD9 (red). Because this CD9 stained area did not overlap with the CX3CR1-gfp + area (green) and was small in size, we concluded CD9 was likely expressed by platelets bound to nonclassical monocyte subset 4. Although it is well-known that monocytes bind platelets, [53] [54] [55] our data illustrate that this function seems to be only for specific subsets of monocytes, rather than a function of all monocytes.
Monocyte Subsets in CAD
Since monocytes are known to play an important role in CAD, 11, [16] [17] [18] 23 we examined frequencies of our newly identified monocyte populations in subjects with CAD. We performed conventional flow cytometry on PBMCs from 18 recruited subjects undergoing medically necessary coronary angiography at the University of Virginia (Table II in the online-only Data Supplement). Patients were stratified on the basis of CAD severity using the Gensini score index as CADlo (score 0-6) to CADhi (score >30). The CADlo subjects are considered as the control group since they have no stenosis. Conventional flow cytometry on CADhi versus CADlo subjects showed no differences in any of the classical subset frequencies ( Figure 5A ). In addition, these classical subsets have shown no apparent disparity in their capacity to take-up either LDL ( Figure 3C ) or oxLDL ( Figure 3D ) particles. However, we found that the frequency of Slan − nonclassical monocytes (subset 7; P=0.002) was significantly reduced, whereas the frequency of Slan + monocytes (subsets 4+5; P=0.03) was significantly increased in CADhi subjects compared with CADlo subjects ( Figure 5B) . Moreover, the frequency of Slan + nonclassical monocytes showed a trending positive correlation with subjects' Gensini scores, suggesting that the Slan + nonclassical monocyte population increases with CAD severity (left; Figure 5C ). In addition, Slan protein expression levels showed a statistically significant correlation with CAD disease severity (right; Figure 5C ).
Slan + Nonclassical Monocyte Function
We next examined how Slan + monocytes may impact CAD progression. The first question we asked was why did we observe more of these Slan + nonclassical monocytes in the CADhi subjects as compared with CADlo subjects. CXCR6 is a chemokine receptor expressed on different immune cells 56 and has been shown to play a role in CAD. Immune cells expressing CXCR6 respond/migrate to activated endothelial cells expressing the CXCR6 ligand CXCL16. 57 As shown in Figure 4C , CXCR6 was solely expressed in Slan + monocytes. Therefore, we performed a transwell migration assay using CXCL16 ( Figure 6A CXCR6 mediated adhesion of monocytes to atherosclerotic plaque endothelium. 58 Finally, we examined the ability of the nonclassical monocytes to phagocytose or engulf apoptotic cells. Efferocytosis, the process by which dying cells are phagocytosed, is an important monocyte function in regulation of CAD progression. 59 Previous studies have shown that efferocytosis by myeloid cells of apoptotic vascular cells and apoptotic macrophages is critical for preventing the progression of atherosclerosis through maintenance of vascular homeostasis. 4, 60 Tabas and others have elegantly shown that efferocytosis becomes defective in advanced human atherosclerotic plaques and when this process is disrupted in ApoE −/− mice plaque necrosis and instability increases. 61, 62 As shown in Figure 6B , among the nonclassical subsets, the Slan + cluster (subset 5; P=0.004) engulfed more apoptotic thymocytes than its Slan − (subset 7) counterpart. These data suggest that the Slan + nonclassical monocytes contribute to efferocytosis and maintenance of vascular homeostasis.
Discussion
The current study establishes a new paradigm that human monocyte subsets are heterogeneous. The high dimensional, unbiased, single-cell analysis of 34 phenotypic markers described here provides a global landscape of human blood monocytes by capturing both their complexity and heterogeneity. Using a combination of clustering algorithms, we identified 8 monocyte subsets within human blood of normal healthy individuals and in subjects with CAD. Of these 8 subsets, 4 were part of the larger known classical monocyte subset as is conventionally defined by the marker CD14. The nonclassical monocytes were separated into 3 clusters and the intermediate monocytes did not show any subclassification. In blood of subjects with high/severe CAD as measured by coronary angiography, we found significant changes in frequencies of a Slan + nonclassical subset. A positive Pearson correlation with the Gensini score used for CAD severity suggested that nonclassical monocyte-specific Slan protein expression might be an important biomarker for CAD progression.
Automated unsupervised analysis to define cellular subpopulations can greatly increase the efficiency and reproducibility of high-dimensional cytometric data analysis. 63, 64 Dimensionality reduction techniques such as t-SNE are helpful in visualizing data. Since t-SNE embeds data in a way that preserves neighborhoods, yet, does not completely preserve the distance and density information of a data set, 65 we used FlowSOM, a method based on building the SOM grid and downstream consensus clustering, to identify new monocyte subsets in an unbiased manner. Recently, this method has been shown to be the most suited algorithm for cell subset discovery. 66 By using FlowSOM-based clustering, we successfully identified the intermediate monocytes (subset 3; Figures 2  and 4 ) as a separate subset from both nonclassical and classical monocytes, validating its usefulness to accurately identify monocyte subsets. FlowSOM also correctly separated the classical IgE + subset (subset 8; Figures 2 and 3 ) corresponding with the IgE-binding CD2 + FcεR1
+ classical subset described in the literature. 44 We verified the FlowSOM results, using a second clustering method, PhenoGraph, a graph-based partitioning method ( Figure IVE in Figure 2D , we concluded that FlowSOM clustering was more accurate than PhenoGraph in this regard. As is widely accepted, intermediate monocytes can be distinguished from nonclassical monocytes on the basis of their CD14 expression, which was clearly expressed on intermediate subset 3 and not on nonclassical subset 7.
Three nonclassical monocytes could be distinguished with our CyTOF panel: 1 Slan − and 2 Slan + subsets. Slan is a 6-sulfo LacNac residue on an O-linked carbohydrate moiety of PSGL-1 recognized by the antibody M-DC8. 46 From our RNA-sequencing data Slan + nonclassical had a higher B3GALT2 gene expression compared with the Slan − nonclassical monocytes. B3GALT2 is a β-1,3-galactosyltransferase enzyme involved in protein glycosylation and is most likely involved in the generation of Slan.
49,50 PSGL-1 is widely expressed on immune cells and its functionality depends highly on posttranslational modifications. For example, PSGL-1 on monocytes and neutrophils needs tyrosine sulfate to be able to adhere to the P-selectin and sialylated O-linked glycans to bind E-selectin expressed on activated/stressed endothelium. 48 Selectins mediate the initial rolling interaction of leukocytes on vascular endothelium before extravasation. Slan is neither sialylated nor is it located on a tyrosine and is therefore likely not involved in E-or P-selectin binding. 46 Indeed, we observed equivalent adhesion of Slan + and Slan − nonclassical monocyte subsets to activated human aortic endothelial cells ( Figure 6C ).
Nonclassical monocytes have been shown to play a protective role in CAD. We have previously shown that the nuclear receptor Nr4a1 is needed for nonclassical monocyte development 21, 22 and that when Nr4a1 −/− mice were either crossed with the atherogenic ApoE −/− mice or bone marrow was transplanted to atherogenic Ldlr −/− mice there was an impressive 3-fold increase in atherosclerotic lesion area. [23] [24] [25] In addition, bone marrow from mice selectively lacking nonclassical monocytes (E2 −/− ) transplanted to atheroprone Ldlr −/− mice fed a western diet showed a 2-fold increase in lesion area compared with wild-type mice. 18, 22 These nonclassical monocytes are likely atheroprotective by means of their role in oxLDL uptake, vascular repair, and cholesterol efflux. 4, 18 Slan + nonclassical monocytes expressed CXCR6 and were able to migrate toward the chemokine CXCL16, unlike the Slan − nonclassical monocytes. Migration of Slan + nonclassical monocytes towards CXCL16 occurred despite their relatively low CXCR6 surface expression by flow cytometry (data not shown). Other groups have confirmed that monocytes can migrate to CXCL16. 58, 67 Both CXCR6 and CXCL16 have been shown to be expressed in human atherosclerotic plaques. 67, 68 Could these Slan + nonclassical monocytes be considered atheroprotective or would they be more likely to play an aggravating role? Slan + nonclassical monocytes showed a very low expression of known monocyte activation markers CD40 and CD63 compared with all other subsets, indicating that these cells may play an atheroprotective role. It has been shown that CD40 + monocytes are proinflammatory and, corresponding with our CyTOF data in Figure 2D , CD40 is most highly expressed on intermediate monocytes. 69 Unlike other monocyte subsets, Slan + monocytes have several surface markers in common with dendritic cells. 46, 70 In this study, we demonstrated that compared with other nonclassical monocytes the Slan + nonclassical monocytes have a higher capacity to engulf apoptotic cells. Efferocytosis has been shown to be beneficial in CAD in successfully limiting disease progression. 60 This process becomes defective in advanced human atherosclerotic plaques; and when it is disrupted in ApoE −/− mice, plaque necrosis, and instability increases. 61, 62 Taken together, our data suggest that the Slan + nonclassical monocytes are likely anti-inflammatory and contribute to efferocytosis and maintenance of vascular homeostasis in late atherogenesis. Therefore, we suggest that in CAD these Slan + nonclassical monocytes are induced in a compensatory manner to attempt to resolve the plaque and prevent atherosclerosis progression. Further studies will be needed to fully elucidate this.
In summary, we provide evidence that human nonclassical monocytes are a heterogeneous population, existing of several subsets with functional differences. These subsets have changed frequencies in the setting of severe CAD. One of these subsets, Slan + CXCR6
+ nonclassical monocytes may prove to be a useful target in preventing CAD progression. Detailed studies of these new subsets could unravel their signatures and identify novel biomarkers in disease.
